Drug intelligence / Profile preview

Inmunoferon

Development stage: Preclinical
Lead developer: Cantabria Labs
Administration: Oral

Overview

Inmunoferon is an oral dietary supplement developed by Industrial Farmacéutica Cantabria, S.A. (Cantabria Labs). It is formulated to strengthen and modulate the immune system, and is being investigated for its potential effects on biological aging. The supplement contains a patented technology called AM3 (a glycoconjugate of phosphorylated alpha glucomannan and soy protein), Hesperidin, Spermidine, and Zinc. Its mechanism of action involves regulating inflammatory responses, inhibiting pro-inflammatory cytokines like TNF-alpha, enhancing the function of various immune cells, and promoting cellular processes such as autophagy, which is crucial for cellular health and anti-aging effects.

Brand names: Inmunoferon
Other names: AM3AM-3AM 3glycophosphopeptical complex

Targets

NeuraminidaseTNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Inmunoferon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inmunoferon.

Explore the full profile